You are here: Industry Insights > Sandoz

News List

Sandoz receives EU approval in Europe for Rixathon (biosimilar rituximab) europeanpharmaceuticalreview
July 05, 2017
The EC has approved Sandoz’ Rixathon (biosimilar rituximab) for use in Europe. Rixathon is approved for use in all indications of the reference medicine…
Sandoz receives EU approval for Erelzi (biosimilar etanercept) europeanpharmaceuticalreview
July 03, 2017
The European Commission (EC) has approved Sandoz’ (a Novartis division) Erelzi (biosimilar etanercept) for use in Europe, to treat inflammatory diseases…
EC approves Sandoz’s Rixathon for blood cancer and immunological diseases pharmaceutical-technology
June 21, 2017
Novartis division Sandoz’s Rixathon (biosimilar rituximab) has received approval from the European Commission (EC) to treat blood cancers and immunological diseases in Europe.
Durect and Sandoz sign $293m deal to commercialise Posimir in US pharmaceutical-technology
May 10, 2017
Durect has signed a development and commercialisation agreement with Sandoz, a division of Novartis, to develop and market Posimir (Saber-Bupivacaine) in the US.
Sandoz proposed biosimilars recommended for EU approval europeanpharmaceuticalreview
April 26, 2017
The Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions to treat the same indications as their respective reference medicines.
Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe cphi-online
April 25, 2017
Company receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers.
DSM Sinochem Pharmaceuticals in agreement with Sandoz financialexpress
March 17, 2017
The agreement will licence certain DSP intellectual property assets for the manufacture of beta lactam antibiotics
Sandoz biosimilar adalimumab study shows equivalent efficacy europeanpharmaceuticalreview
March 15, 2017
Sandoz, a Novartis division, presented data for its proposed biosimilar adalimumab, GP2017. Their Phase 3 confirmatory efficacy, safety and immunogenicity study met its primary endpoint, demonstrating GP2017 has equivalent efficacy to the reference medici
Sandoz announces winners of inaugural Healthcare Access Challenge #SandozHACk worldpharmanews
March 14, 2017
Sandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare Access Challenge (Sandoz HACk).
Sandoz proposed biosimilar adalimumab demonstrates equivalent efficacy as Humira cphi-online
March 08, 2017
Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

Previous page 1 2 3 4 5 6 7 8 Next page